Molecular Biology
Reverse Transcriptase
RNA-dependent DNA polymerase — cDNA synthesis, retroviruses, telomerase, and the enzyme that ran the dogma backward
Reverse transcriptase is an RNA-dependent DNA polymerase — an enzyme that reads an RNA template and writes a complementary DNA (cDNA) strand, reversing the normal DNA-to-RNA flow of the central dogma. Retroviruses such as HIV-1 carry it inside the virion to convert their single-stranded RNA genome into double-stranded proviral DNA that integrates into the host chromosome; the same reaction drives LINE-1 and LTR retrotransposons (about 42% of the human genome) and telomerase, which caps our chromosome ends. Because the retroviral enzyme has no proofreading exonuclease, it misincorporates roughly one base every 1,700 to 10,000 nucleotides, generating the mutation storm that lets HIV outrun drugs. It was discovered independently in 1970 by Howard Temin and David Baltimore, who shared the 1975 Nobel Prize with Renato Dulbecco, and it now powers RT-PCR, cDNA cloning, and RNA sequencing.
- ReactionRNA template → DNA (cDNA)
- Activities in one proteinRdDP · DdDP · RNase H
- Error rate (HIV RT)~1 in 1,700–10,000 nt
- ProofreadingNone (no 3'→5' exonuclease)
- DiscoveredTemin & Baltimore, 1970
- Nobel Prize1975 (with Dulbecco)
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
Why reverse transcriptase matters
- It rewrote the central dogma. Before 1970, molecular biology taught that genetic information flowed one way: DNA to RNA to protein. Reverse transcriptase proved that information can move backward from RNA into DNA, forcing the field to accept RNA genomes that permanently insert themselves into host chromosomes. Nature's news headline literally read "Central dogma reversed."
- It is the drug target that made HIV survivable. Reverse transcriptase is the first enzyme HIV uses after entry, so it was the first antiretroviral target. Zidovudine (AZT), a nucleoside analog that chain-terminates the growing cDNA, was approved in 1987; today nucleoside (NRTI) and non-nucleoside (NNRTI) reverse-transcriptase inhibitors are the backbone of nearly every combination regimen that has turned HIV from a death sentence into a managed chronic condition.
- It built the tools of modern gene expression science. RT-PCR, RT-qPCR, cDNA libraries, and RNA-seq all start by reverse-transcribing RNA into DNA. The RT-qPCR tests that detected SARS-CoV-2 during the pandemic worked precisely because that virus, like HIV, has an RNA genome that must be copied to DNA before it can be amplified.
- It runs constantly inside your own cells. Telomerase, a specialized reverse transcriptase, extends chromosome ends every division in stem cells, germ cells, and about 90% of cancers. LINE-1 retrotransposons encode a reverse transcriptase that still jumps around the genome — one such insertion into the factor VIII gene has caused hemophilia A.
- It shaped the genome itself. Retrotransposons and endogenous retroviruses, all products of reverse transcription, make up roughly half of human DNA. Processed pseudogenes, retrocopied genes, and even some regulatory elements are fossils of past reverse-transcription events written permanently into our chromosomes.
- It powers next-generation genome editing. Prime editing fuses a reverse transcriptase to a nickase Cas9, letting the enzyme write new sequence directly from an extended guide RNA — small insertions, deletions, and all twelve possible point-mutation corrections without a double-strand break.
Common misconceptions
- "Reverse transcriptase violates the central dogma." It does not. Crick's dogma forbids information flowing out of protein back into nucleic acid; it never forbade RNA-to-DNA. Crick even drew RNA→DNA as a theoretically permitted arrow in 1958. Reverse transcriptase overturned the popular simplification "DNA makes RNA makes protein," not the dogma as Crick actually stated it.
- "It is just a backward version of ordinary transcription." Transcription (RNA polymerase) makes RNA from DNA and needs no primer. Reverse transcriptase makes DNA from RNA, requires a primer with a free 3'-OH (retroviruses use a host tRNA), and carries an RNase H activity to destroy the template as it goes — features RNA polymerase entirely lacks.
- "Only viruses have reverse transcriptase." Telomerase is a cellular reverse transcriptase essential for chromosome maintenance, and LINE-1 retrotransposons encode an active one in every human cell. Reverse transcription is a normal part of eukaryotic biology, not a purely viral phenomenon.
- "The enzyme is unreliable, so it is a poor enzyme." Its low fidelity is a feature, not a defect, for the virus: error-prone copying generates the diversity that fuels immune escape and drug resistance. Its speed (adding hundreds of nucleotides per second in vitro) is perfectly adequate; it simply trades accuracy for evolvability.
- "cDNA is the same as the gene." cDNA is copied from mature, spliced mRNA, so it lacks introns and the promoter — it captures only the expressed, processed sequence. That is exactly why cDNA is preferred for expressing human proteins in bacteria, which cannot splice.
- "Reverse transcriptase and integrase are the same thing." They are distinct enzymes, though both are encoded by the retroviral pol gene and packaged in the virion. Reverse transcriptase makes the double-stranded DNA copy; integrase then splices that DNA into the host chromosome. HIV drugs target each separately.
How reverse transcriptase works, step by step
Retroviral reverse transcriptase is a molecular multitasker: a single polypeptide (in HIV-1, the mature enzyme is a p66/p51 heterodimer processed from the Gag-Pol polyprotein) carries three activities — RNA-dependent DNA polymerase, DNA-dependent DNA polymerase, and RNase H. Reverse transcription of a retroviral genome is a choreographed, template-switching relay, not a simple one-pass copy.
1. Priming. The enzyme cannot start from scratch; like every DNA polymerase it needs a primer with a free 3'-hydroxyl. HIV-1 hijacks a host transfer RNA, tRNA-Lys3, which the virion pre-packages annealed to a sequence near the 5' end of the RNA genome called the primer-binding site (PBS). Synthesis begins from the tRNA's 3' end.
2. Minus-strand synthesis and the first jump. The RdDP activity copies leftward to the 5' end of the genome, producing a short DNA called minus-strand strong-stop DNA. RNase H then degrades the RNA that has already been copied. Because retroviral genomes carry identical repeat (R) sequences at both ends, the short DNA can hop to the 3' end of the genome (or the co-packaged second genome) and re-anneal — the first strand transfer.
3. Extending the minus strand. Reverse transcriptase now copies the rest of the genome into a continuous minus-strand DNA, with RNase H trailing behind and chewing up the spent RNA template. RNase H leaves one RNA fragment intact: a purine-rich stretch called the polypurine tract (PPT), which resists degradation.
4. Plus-strand synthesis and the second jump. The surviving PPT serves as the primer for the DNA-dependent DNA polymerase activity, which now synthesizes the plus strand off the minus-strand DNA template. A second strand transfer, guided by the PBS sequences, brings the two strands together.
5. Completion. The polymerase finishes both strands, generating a full-length, blunt-ended, linear double-stranded DNA in which the two long terminal repeats (LTRs) — assembled from the U3, R, and U5 elements — now flank the entire genome. This proviral DNA is the substrate for the separate viral enzyme integrase, which inserts it into a host chromosome, where it becomes a permanent provirus transcribed by the host's own RNA polymerase II.
Telomerase runs the same core chemistry with a crucial difference: it brings its own template. Its catalytic subunit TERT is a bona fide reverse transcriptase, but the RNA it copies (TERC/hTR) is an intrinsic subunit containing a short 5'-CUAACCCUAAC-3' template that TERT reads repeatedly to add TTAGGG repeats to the 3' overhang of each chromosome, counteracting the end-replication problem.
Reverse transcriptase vs. other polymerases
| Property | Reverse transcriptase (retroviral) | Replicative DNA polymerase (Pol III / δ) | RNA polymerase II | Telomerase |
|---|---|---|---|---|
| Template | RNA (then DNA) | DNA | DNA | Intrinsic RNA subunit |
| Product | DNA (cDNA) | DNA | RNA | DNA (TTAGGG repeats) |
| Primer needed? | Yes — host tRNA | Yes — RNA primer | No | 3'-OH of chromosome end |
| Proofreading (3'→5' exo) | No | Yes | No (limited backtrack) | No |
| Error rate (per base) | ~10⁻³ to 10⁻⁴ | ~10⁻⁷ (with proofreading) | ~10⁻⁴ to 10⁻⁵ | Low (short fixed template) |
| RNase H activity | Yes | No | No | No |
| Direction of synthesis | 5'→3' | 5'→3' | 5'→3' | 5'→3' |
Where reverse transcription happens
| System | Enzyme source | Template | Fate of product | Genome footprint |
|---|---|---|---|---|
| Retrovirus (HIV, HTLV) | Virion-packaged viral RT | Viral ssRNA genome | Integrated provirus | Infectious, spreads |
| LTR retrotransposon | Element-encoded RT | Element mRNA | New genomic insertion | ~8% of human DNA (with HERVs) |
| LINE-1 (non-LTR) | ORF2p RT + endonuclease | L1 mRNA (and Alu/SVA in trans) | Target-primed insertion | ~17% (L1) + Alu/SVA → ~one-third |
| Telomerase | Cellular TERT + TERC RNA | Built-in 11-nt RNA | Extends chromosome ends | Essential, not inserted |
| Hepatitis B (pararetrovirus) | Viral P protein RT | Pregenomic RNA | Partly dsDNA in capsid | Episomal cccDNA |
| Lab RT-PCR / cloning | Engineered MMLV / AMV / Tth | Any mRNA | cDNA for analysis | None (in vitro) |
The discovery and famous experiments
- Temin's provirus hypothesis (1964). Howard Temin noticed that Rous sarcoma virus, an RNA tumor virus, was blocked by inhibitors of DNA synthesis and by actinomycin D (a DNA-dependent transcription inhibitor). He proposed the heretical idea that the RNA virus replicates through a DNA "provirus" integrated into the host genome — a claim that implied information could flow from RNA to DNA and was dismissed for years.
- The 1970 discovery. On 27 June 1970, Nature published back-to-back papers: Temin and Satoshi Mizutani reported an "RNA-dependent DNA polymerase in virions of Rous sarcoma virus," and David Baltimore independently reported the same enzymatic activity in murine leukemia and Rous sarcoma virions. Both showed that purified virus particles contain an enzyme that makes DNA from an RNA template — direct proof of reverse transcription.
- The 1975 Nobel Prize. Howard Temin and David Baltimore shared the Nobel Prize in Physiology or Medicine with Renato Dulbecco "for their discoveries concerning the interaction between tumour viruses and the genetic material of the cell." Temin was 40; the provirus hypothesis he had defended alone for years was fully vindicated.
- Telomerase (1985). Carol Greider and Elizabeth Blackburn discovered telomerase in Tetrahymena, showing that a cellular enzyme adds telomeric repeats using an RNA template — a reverse transcriptase native to eukaryotes. They shared the 2009 Nobel Prize with Jack Szostak, cementing reverse transcription as normal cell biology.
- AZT and the drug era (1985–1987). Following the identification of HIV, researchers repurposed zidovudine (AZT), a thymidine analog first synthesized in 1964, as a reverse-transcriptase chain terminator. Its 1987 approval, the fastest FDA approval to that date, launched the antiretroviral era and validated reverse transcriptase as the premier antiviral drug target.
Frequently asked questions
What does reverse transcriptase do?
Reverse transcriptase is an RNA-dependent DNA polymerase — it reads an RNA template and synthesizes a complementary DNA (cDNA) strand, the opposite direction to normal transcription. The retroviral enzyme is actually three activities fused into one protein: an RNA-dependent DNA polymerase makes the first DNA strand off the RNA, an RNase H domain chews away the now-redundant RNA of the RNA:DNA hybrid, and a DNA-dependent DNA polymerase then copies the first DNA strand into a double-stranded product. Like all DNA polymerases it extends a primer 5' to 3' and needs a 3'-hydroxyl to start; retroviruses supply that primer with a host transfer RNA (tRNA-Lys3 in HIV-1) annealed to the primer-binding site. The net result of a full reverse-transcription cycle is a double-stranded DNA copy of a single-stranded RNA genome, ready to integrate into the host chromosome.
Does reverse transcriptase break the central dogma?
It bends it, but it does not break it. Francis Crick's central dogma states that sequence information, once passed into protein, cannot come back out — it never forbade RNA-to-DNA flow. Crick actually drew RNA-to-DNA as a theoretically allowed but unobserved arrow in his 1958 formulation. What reverse transcriptase overturned in 1970 was the textbook simplification 'DNA makes RNA makes protein' as a strictly one-way street. Temin and Baltimore showed information can flow backward from RNA to DNA, which was heretical enough that Nature titled its news piece 'Central dogma reversed.' The finding forced biologists to accept RNA genomes that write themselves into host DNA, and it later revealed that telomerase and retrotransposons run the same reaction constantly inside our own cells.
Why does reverse transcriptase make so many mutations?
Retroviral reverse transcriptase has no 3'-to-5' proofreading exonuclease, the built-in spell-checker that replicative DNA polymerases use to excise mismatched nucleotides. Without it, HIV-1 reverse transcriptase misincorporates roughly one wrong base every 1,700 to 10,000 nucleotides — and the HIV genome is only about 9,700 bases, so on average every new genome carries at least one mutation. Multiplied across the roughly 10 billion virions an untreated patient produces daily, the virus explores essentially every possible single-point mutation every day. That error-prone copying is not a bug for the virus; it is the engine of antigenic escape and drug resistance, which is exactly why HIV must be hit with three drugs at once (combination antiretroviral therapy) rather than one.
What is the difference between reverse transcriptase and telomerase?
Telomerase is a specialized reverse transcriptase — its catalytic subunit TERT is genuinely an RNA-dependent DNA polymerase — but it carries its own tiny RNA template built in, rather than copying a foreign RNA. The TERC (or hTR) RNA component contains a short template (5'-CUAACCCUAAC-3' in humans) that TERT reads over and over to add the TTAGGG repeat to chromosome ends, offsetting the end-replication problem that shortens telomeres each division. So retroviral RT copies a whole viral genome once per infection and then is discarded; telomerase copies the same eleven-nucleotide template repeatedly and is a permanent cellular ribonucleoprotein. Both use the same chemistry, and telomerase's discovery by Carol Greider and Elizabeth Blackburn in 1985 (2009 Nobel Prize) confirmed that reverse transcription is a normal, essential part of our own biology, not just a viral trick.
How is reverse transcriptase used in the lab?
Reverse transcriptase is the enzyme that turns RNA into DNA so molecular biologists can work with it. In RT-PCR, RT first copies messenger RNA into cDNA, then a DNA polymerase amplifies that cDNA — the standard way to measure gene expression and the basis of the RT-qPCR tests used to detect SARS-CoV-2, an RNA virus. cDNA library construction reverse-transcribes the entire mRNA pool of a tissue into clonable, intron-free DNA that captures which genes are actually being expressed. RNA-seq relies on the same first step to make sequenceable libraries. Engineered enzymes dominate: MMLV-derived reverse transcriptases (SuperScript, and RNase-H-minus variants) and the thermostable enzyme from Thermus thermophilus give higher fidelity, longer reads, and tolerance to structured RNA than the wild-type viral proteins. Reverse transcriptase also powers prime editing, a CRISPR variant that fuses an RT to Cas9 to write new sequence directly from a guide RNA template.
Who discovered reverse transcriptase?
Howard Temin and David Baltimore discovered it independently and published back-to-back in Nature on 27 June 1970. Temin, at the University of Wisconsin working with Satoshi Mizutani, had argued for nearly a decade that RNA tumor viruses replicate through a DNA intermediate — his 'provirus hypothesis,' widely dismissed as impossible because it violated the accepted flow of genetic information. Baltimore, then at MIT, found the same activity in virions of murine leukemia virus and Rous sarcoma virus. Both showed that purified virus particles contain an enzyme that synthesizes DNA using the viral RNA as template. The vindication was total: Temin and Baltimore shared the 1975 Nobel Prize in Physiology or Medicine with Renato Dulbecco for the discovery of this interaction between tumor viruses and the genetic material of the cell.
Do human cells make their own reverse transcriptase?
Yes — abundantly. Beyond telomerase, the human genome is riddled with retrotransposons that encode reverse transcriptase. LINE-1 (L1) elements make up about 17% of the genome and encode an ORF2p protein with reverse-transcriptase and endonuclease activity that copies L1 and, in trans, the non-autonomous Alu and SVA elements; together these retroelements account for roughly 42% of human DNA. Only about 80 to 100 L1 copies are still capable of jumping, but their reverse transcriptase causes new insertions that occasionally disrupt genes — documented cases include hemophilia A from an L1 insertion into factor VIII. Endogenous retroviruses (HERVs), fossilized retroviral genomes making up about 8% of the genome, carry their own decayed RT genes. So reverse transcription is not a foreign intrusion but a constant, genome-shaping process running inside our own chromosomes.